UK to add Sinovac, Sinopharm, Covaxin to list of approved vaccines – Outney.net

The British government said it would recognize China’s Sinovac and Sinopharm vaccines.

The change, which will take effect on November 22, means that travelers who have received these two vaccines will be considered fully vaccinated in Britain.

Covaxin India is also included in the UK updated list of approved vaccines.

Passengers arriving in the UK after being fully vaccinated and receiving a vaccination certificate from one of more than 135 approved countries and territories are no longer required to take a pre-departure test, an eight-day test or isolate upon arrival .

Those who have proof of vaccination from a country or territory that is not listed, or with a vaccine that is not listed, should follow the rules for persons who do not qualify as fully vaccinated.

The list of currently approved vaccines includes Pfizer BioNTech, Oxford AstraZeneca (including Covishield), Moderna and (J&J).

Furthermore, the British government has said that from 22 November, all persons under the age of 18 traveling to England will be treated as fully vaccinated at the border and will be exempt from incoming self-isolation requirements, eight-day testing and testing before departure. .

They will be asked to take a post-arrival test and a free PCR confirmatory test if they test positive.

The British Department of Transportation said on Monday that travel rules are being further simplified as all people under the age of 18 will be treated as fully vaccinated at the border and will be able to enter England without being isolated upon arrival.

British Transport Secretary Grant Shapps said the announcement marks the next step in resuming international travel.

More than 87 percent of people aged 12 and over in the country have received the first dose of the vaccine and more than 79 percent have received both doses, the latest figures show. At the same time, more than 17 percent have received booster injections, or third doses of a coronavirus vaccine.